From biology to clinical experience: Evolution in the knowledge of neuroendocrine tumours

Research output: Contribution to journalArticlepeer-review


Neuroendocrine tumours (NETs) represent a group of neoplasias characterized by significant histopathological and biological heterogeneity. Diagnosis of neuroendocrine tumours relies upon histological examination augmented by newer techniques, such as pet-dotatoc scan. Surgery represents the only curative therapeutic approach. In advanced unresectable disease, medical treatment is the best choice. Somatostatin analogues allow adequate control of the carcinoid syndrome with a low effect on tumour cell growth. Chemotherapy has a good activity only in poor prognosis patients. According to the clinical course of the disease, a multimodal approach could be evaluated in selected cases. New target therapy including multikinase inhibitors, monoclonal antibody and m-tor inhibitors is now under clinical investigation for the treatment of advanced NETs. Preliminary results demonstrated a good activity in terms of disease control rate and tumour shrinkage.

Original languageEnglish
Pages (from-to)79-87
Number of pages9
JournalOncology Reviews
Issue number2
Publication statusPublished - Jun 2009


  • Angiogenesis
  • Chemotherapy
  • Metastasis
  • Neuroendocrine tumours
  • Target therapy

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'From biology to clinical experience: Evolution in the knowledge of neuroendocrine tumours'. Together they form a unique fingerprint.

Cite this